- FDA Meeting – Risk Benefit Assessment
Public Comments on Benefit-Risk Assessment in Drug Regulatory Decision-Making
Docket No. FDA-2017-N-4076
My name is Caila Brander and I am the Policy Coordinator at The National Women’s Health Network, a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and, by choice, we do not accept financial support ...
- FDA Meeting – Off-Label Use of Medical Products
Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and do not accept financial support from insurance companies, drug companies, or medical device manufacturers. Since the NWHN’s founding 40 ...
- FDA Comments – Real World Evidence & Essure
Comments on the Draft Guidance: Use of Real-World Evidence to Support Regulatory Decision Making for Medical Devices
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and do not accept financial support from insurance companies, drug companies or medical ...
- FDA Scientific Workshop – Labeling of Low-dose Vaginal Estrogen Products
Statement of Cindy Pearson, Executive Director, National Women’s Health Network
Food and Drug Administration Scientific Workshop on Labeling Lower-Dose Estrogen-Alone Products for Symptoms of Vulvar and Vaginal Atrophy
My name is Cindy Pearson, and I am the Executive Director of The National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that works to ...
- FDA Scientific Workshop – Drug Interactions with Hormonal Contraceptives
Statement of Christina Cherel, Program Coordinator, National Women’s Health Network
Food and Drug Administration Hormal Contraception Public Workshop on Drug Interactions with Hormonal Contraceptives: Public Health and Drug Development Implications
My name is Christina Cherel, and I am the Program Coordinator at the National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that ...
- FDA Meeting – Osteoporosis Drug Development
Statement of Christina Cherel, Program Coordinator, National Women’s Health Network
Food and Drug Administration Meeting of the Division of Bone, Reproductive, and Urologic Products in the Center for Drug Evaluation and Research.
“Osteoporosis Drug Development: Moving Forward”
My name is Christina Cherel, and I am the Program Coordinator at The National Women’s Health Network. The National Women’s Health Network ...
- FDA Meeting – Essure
Statement of Cindy Pearson, Executive Director, National Women’s Health Network
Food and Drug Administration Meeting of the Obstetrics and Gynecology Devices Panel
My name is Cindy Pearson, and I am the Executive Director of The National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all ...
- FDA Meeting – Generic Drug Labeling
Statement of Coco Jervis, J.D., Program Director
Food and Drug Administration Public Meeting on Supplemental Applications Propsing Labeling Changes for Approved Drugs and Biological Products
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory decision-making bodies. ...
- FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder
Statement of Cindy Pearson, Executive Director, National Women’s Health Network
Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder
I am speaking on behalf of the National Women’s Health Network, a non-profit advocacy organization that works to improve the health of all women. We are supported by our members, and do not take financial contributions ...
- FDA Meeting – Lorcaserin
Statement of Kate Ryan
Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Meeting on Lorcaserin
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory decision-making bodies. We are supported by our members and do not take ...
- FDA Meeting – Qnexa Safety and Efficacy
Statement of Kate Ryan
Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee Meeting
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory decision-making bodies. We are supported by our members and do not take financial contributions from ...
- FDA Meeting – Naltrexone/Bupropion (Contrave)
Statement of Kate Ryan, Program Coordinator
Food and Drug Administration (FDA) Gastroenterology Endocrinologic and Metabolic Drugs Advisory Committee
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to the policy and regulatory decisionmaking bodies. We are supported by our members and ...
